News Article Discusses Aethlon Medical HIV/AIDS and Hepatitis-C Clinical Trials
SAN DIEGO--(BUSINESS WIRE)--May 12, 2005--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it is the subject of a news article entitled: "Aethlon Readies To Launch Viral Device Trials in India," published in the latest issue of the IndUS Business Journal. The article can be found on page one of the online edition at www.indusbusinessjournal.com.
About Aethlon Medical
Aethlon Medical is pioneering the development of viral filtration devices to treat drug and vaccine resistant pathogens. The market focus is the treatment of the Human Immunodeficiency Virus (HIV), Hepatitis-C (HCV), and Biological Weapon candidates. Aethlon has an experienced management team, which receives support and guidance from globally recognized science advisors representing the infectious disease, biowarfare, and dialysis industries. Clinical Trials to treat HIV and HCV patients in India are scheduled to begin in the coming months, and U.S. clinical studies are expected to begin later this year. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Aethlon Medical Inc. (ticker: AEMD, exchange: OTC Bulletin Board (.OB)) News Release - Thursday, May 12, 2005
CONTACT: Aethlon Medical, Inc.
Anne Hoversten, 858-459-7800 x300 (Investor Relations) anne@aethlonmedical.com
SOURCE: Aethlon Medical, Inc.